- 25371 Commercentre Dr, Lake Forest, CA 92630
- Patients Results
Explore our full menu of advanced genomic testing solutions for solid tumors, hematologic malignancies, and immunohistochemistry. Powered by cutting-edge DNA and RNA sequencing technologies, our tests are designed to support precision diagnosis, prognostication, therapeutic decision-making, and clinical research.
| Features | Liquid Trace® - Solid Tumor | Solid Tumor Profile Plus™ | Solid Tumor Profile™ | Solid Tumor Fusion / Expression |
|---|---|---|---|---|
|
Tested Genes |
>300 cfDNA / >1600 cfRNA |
>400 cfDNA / >1600 cfRNA |
>400 DNA |
>1600 RNA |
|
TAT |
5-7 Day |
7-10 Day |
5-7 Day |
7-10 Day |
|
Indications |
Chromosomal abnormalities, gene amplifications, HRR
Fusions: ALK, ROS1, RET,
NTRK1/2/3, and more. BRAF, CIC, EWSR1, PD-L1, MET exon 14 skipping and various alternative splicing, MET, HER2, PIK3CA, PTEN, EBV, HPV, Gene amplifications, AKT1, RAS, HER2, MYC, EGFR, TTV, HTLV-1 status, T- & B-cell clonality analysis Monitor therapeutic response |
All solid tumors
Fusions: ALK, ROS1, RET, NTRK1/2/3, and more. BRAF, CIC, EWSR1, PD-L1, MET exon 14 skipping and various alternative splicing, MET, HER2, EGFR, Gene amplifications, PIK3CA, PTEN, TTV, AKT1, RAS, TMB, MSI, EBV, HPV, HTLV-1 status, and HRD Cancer of unknown primary (CUP) T- & B-cell clonality analysis |
All solid tumors: Mutations in 434 genes, copy number variation and chromosomal structural abnormalities, TMB, MSI, HRD |
All Solid tumors Fusion: ALK, ROS1, RET, BRAF, NTRK1/2/3, FGFR1/2/3/4, CIC, EWSR1 & other sarcoma genes Expression: PD-L1, MYC, CCND1, MET, FGFR1/2/3/4, Ki67, ERBB2, MDM2, EBV, HPV, HTLV-1 status Alternative splicing: MET exon 14 skipping, EGFRvIII, NTRK, Mutations in more than 1600 genes, TTV, T- & B-cell clonality analysis |
|
Sample Type |
Peripheral blood, Plasma, CSF |
FFPE |
FFPE |
FFPE |
|
Sample Requirements |
Peripheral blood: 8-10 mL. EDTA tube preferred CSF: 7-10 mL. Clear tubes |
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative |
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative |
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative |
|
Results Reported |
DNA+RNA |
DNA+RNA |
DNA |
RNA |
|
Clinical Utility |
Monitoring Therapeutic Prognostic Heterogeneity Clinical Trial Matching |
Monitoring Therapeutic Prognostic Heterogeneity Clinical Trial Matching |
Monitoring Therapeutic Prognostic Heterogeneity Clinical Trial Matching |
Monitoring Therapeutic Prognostic Heterogeneity Clinical Trial Matching |
|
Learn More |
Explore Test |
Explore Test |
Explore Test |
Explore Test |
| Features | Liquid Trace® - Hematology | Hematology Profile Plus™ | Hematology Profile™ |
|---|---|---|---|
|
Tested Genes |
>300 cfDNA / >1600 cfRNA |
>300 cfDNA / >1600 cfRNA |
>300 DNA |
|
TAT |
5-7 Day |
7-10 Day |
5-7 Day |
|
Indications |
All hematologic neoplasms
including lymphoma
multiple myeloma, acute lymphoblastic leukemia,
acute myeloid leukemia,
MDS, TTV, CMML, MPN,
VEXAS syndrome, EBV, and HRV, HTLV1 status and quantification
Chromosomal abnormalities, and gene amplifications,
T- & B-cell clonality analysis
Monitor therapeutic response |
All hematologic neoplasms including lymphoma
Classification and diagnosis of lymphoma, multiple myeloma, acute lymphoblastic leukemia, and acute myeloid leukemia
Includes IgHv
Chromosomal abnormalities, EBV, HRV, HTLV-1 status, and gene amplifications, TTV,
T- & B-cell clonality analysis |
All hematologic neoplasms
including lymphoma
MDS, CMML, AML, MPN (JAK2, CALR, MPL),
MRD, multiple myeloma, and other
hematologic diseases |
|
Sample Type |
Peripheral blood, Plasma, CSF |
Bone marrow,
Peripheral blood,
Fresh tissue
|
Bone marrow,
Peripheral blood,
Fresh tissue
|
|
Sample Requirements |
Peripheral blood: 8-10 mL. EDTA tube preferred CSF: 7-10 mL. Clear tubes |
Bone marrow: 2mL. Peripheral blood: 5 mL. EDTA tube preferred FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative |
Bone marrow: 2mL. Peripheral blood: 5 mL. EDTA tube preferred FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative |
|
Results Reported |
DNA+RNA |
DNA+RNA |
DNA |
|
Clinical Utility |
Monitoring Therapeutic Prognostic Heterogeneity Clinical Trial Matching |
Monitoring Therapeutic Prognostic Heterogeneity Clinical Trial Matching |
Monitoring Therapeutic Prognostic Heterogeneity Clinical Trial Matching |
|
Learn More |
Explore Test |
Explore Test |
Explore Test |
